Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Fuera de horario:
Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100
https://www.corbuspharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 19
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Yuval Cohen Ph.D. | CEO & Director | 907.78k | N/D | 1975 |
| Mr. Sean F. Moran CPA, M.B.A. | Chief Financial Officer | 609.28k | N/D | 1958 |
| Ms. Lindsey Smith | Head of Corporate Communications & Patient Advocacy | N/D | N/D | N/D |
| Ms. Christina Bertsch | Head of Human Resources | N/D | N/D | N/D |
| Dr. Dominic Smethurst M.A., M.D. | Chief Medical Officer | N/D | N/D | 1975 |
Descripción
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Corbus Pharmaceuticals Holdings, Inc. a partir del 1 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 9; Junta: 4; Derechos del accionista: 4; Compensación: 9.
